Sublingual drops.

What sublingual drops are.

Semaglutide or tirzepatide, formulated as drops held under the tongue rather than injected. Both are compounded by a licensed 503A pharmacy and dispensed only after a clinician reviews your history.

There is no FDA-approved sublingual form of either molecule, and no FDA-approved dosing for one. There is also limited published research on how well these molecules are absorbed under the tongue compared with an injection. Your clinician weighs that when deciding whether drops fit. Your clinician sets your dose and schedule, and your prescription label lists exactly how many drops to take and how often.

Semaglutide or tirzepatide.

Semaglutide is a GLP-1 receptor agonist, acting on the receptors the body’s own GLP-1 hormone acts on. Tirzepatide acts on two incretin pathways rather than one, GIP and GLP-1.

Which one is appropriate is a clinical decision, not a preference. It depends on your history, your current medications, and how your body responds over time.

Drops or an injection.

Drops are for people who would rather not inject. If that’s you, say so in your intake. Whether drops are appropriate for you is your clinician’s call.

Compounded, not FDA-approved.

Both sublingual options are prepared by licensed 503A pharmacies against a patient-specific prescription. Compounded medications are not reviewed or approved by the FDA for safety, effectiveness, or quality, and they are not the same product as the brand-name versions, Wegovy® and Zepbound®. They are also not generics — no generic semaglutide or tirzepatide exists.

What’s included.

Every plan includes the medication, the clinician consultation and review, ongoing clinician oversight, and shipping. No membership, no hidden fees. You are not charged unless a clinician approves treatment.

Both come in monthly and quarterly plans. Prices are on the cards above.

Who it isn’t for.

Drops contain the same active ingredient, taken a different way. The same cautions apply as for the injectable forms, and a clinician will tell you if it isn’t for you.

Do not use either medication if you or a family member have ever had medullary thyroid carcinoma (MTC), or if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), or if you have had a serious allergic reaction to semaglutide, tirzepatide or any ingredient in the medication. Both may harm an unborn baby, so they are stopped if you become pregnant, and semaglutide is stopped at least two months before a planned pregnancy.

Tirzepatide can make birth control pills less effective. If you use them, your clinician will advise switching to a non-oral method or adding a barrier method for four weeks after you start and after each dose increase.

Tell your clinician about past pancreatitis, gallbladder or kidney problems, slowed stomach emptying, or diabetic eye disease. Full details are on each product’s safety information page.

“Not yet” and “not for you” are real answers here, and you won’t be charged for hearing one.